Literature DB >> 22931300

Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.

Melanie Z Sakatis1, Melinda J Reese, Andrew W Harrell, Maxine A Taylor, Ian A Baines, Liangfu Chen, Jackie C Bloomer, Eric Y Yang, Harma M Ellens, Jeffrey L Ambroso, Cerys A Lovatt, Andrew D Ayrton, Stephen E Clarke.   

Abstract

Drug-induced liver injury is the most common cause of market withdrawal of pharmaceuticals, and thus, there is considerable need for better prediction models for DILI early in drug discovery. We present a study involving 223 marketed drugs (51% associated with clinical hepatotoxicity; 49% non-hepatotoxic) to assess the concordance of in vitro bioactivation data with clinical hepatotoxicity and have used these data to develop a decision tree to help reduce late-stage candidate attrition. Data to assess P450 metabolism-dependent inhibition (MDI) for all common drug-metabolizing P450 enzymes were generated for 179 of these compounds, GSH adduct data generated for 190 compounds, covalent binding data obtained for 53 compounds, and clinical dose data obtained for all compounds. Individual data for all 223 compounds are presented here and interrogated to determine what level of an alert to consider termination of a compound. The analysis showed that 76% of drugs with a daily dose of <100 mg were non-hepatotoxic (p < 0.0001). Drugs with a daily dose of ≥100 mg or with GSH adduct formation, marked P450 MDI, or covalent binding ≥200 pmol eq/mg protein tended to be hepatotoxic (∼ 65% in each case). Combining dose with each bioactivation assay increased this association significantly (80-100%, p < 0.0001). These analyses were then used to develop the decision tree and the tree tested using 196 of the compounds with sufficient data (49% hepatotoxic; 51% non-hepatotoxic). The results of these outcome analyses demonstrated the utility of the tree in selectively terminating hepatotoxic compounds early; 45% of the hepatotoxic compounds evaluated using the tree were recommended for termination before candidate selection, whereas only 10% of the non-hepatotoxic compounds were recommended for termination. An independent set of 10 GSK compounds with known clinical hepatotoxicity status were also assessed using the tree, with similar results.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22931300     DOI: 10.1021/tx300075j

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  15 in total

Review 1.  The Promise of AI for DILI Prediction.

Authors:  Andreu Vall; Yogesh Sabnis; Jiye Shi; Reiner Class; Sepp Hochreiter; Günter Klambauer
Journal:  Front Artif Intell       Date:  2021-04-14

Review 2.  Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models.

Authors:  Richard J Weaver; Eric A Blomme; Amy E Chadwick; Ian M Copple; Helga H J Gerets; Christopher E Goldring; Andre Guillouzo; Philip G Hewitt; Magnus Ingelman-Sundberg; Klaus Gjervig Jensen; Satu Juhila; Ursula Klingmüller; Gilles Labbe; Michael J Liguori; Cerys A Lovatt; Paul Morgan; Dean J Naisbitt; Raymond H H Pieters; Jan Snoeys; Bob van de Water; Dominic P Williams; B Kevin Park
Journal:  Nat Rev Drug Discov       Date:  2019-11-20       Impact factor: 84.694

3.  Evaluation of Strategies for the Assessment of Drug-Drug Interactions Involving Cytochrome P450 Enzymes.

Authors:  Jelle Reinen; Martijn Smit; Mira Wenker
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-12       Impact factor: 2.441

4.  Synergistic Cytotoxicity from Drugs and Cytokines In Vitro as an Approach to Classify Drugs According to Their Potential to Cause Idiosyncratic Hepatotoxicity: A Proof-of-Concept Study.

Authors:  Ashley R Maiuri; Bronlyn Wassink; Jonathan D Turkus; Anna B Breier; Theresa Lansdell; Gurpreet Kaur; Sarah L Hession; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2017-07-07       Impact factor: 4.030

5.  Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™.

Authors:  Ayako Suzuki; Nancy A Yuen; Katarina Ilic; Richard T Miller; Melinda J Reese; H Roger Brown; Jeffrey I Ambroso; J Gregory Falls; Christine M Hunt
Journal:  Regul Toxicol Pharmacol       Date:  2015-05-16       Impact factor: 3.271

Review 6.  Recent advances of semiconducting polymer nanoparticles in in vivo molecular imaging.

Authors:  Kanyi Pu; Niladri Chattopadhyay; Jianghong Rao
Journal:  J Control Release       Date:  2016-01-08       Impact factor: 9.776

7.  A UPLC-MS/MS application for comparisons of the hepatotoxicity of raw and processed Xanthii Fructus by energy metabolites.

Authors:  Hai Jiang; Liu Yang; Xudong Xing; Meiling Yan; Xinyue Guo; Ajiao Hou; Wenjing Man; Bingyou Yang; Qiuhong Wang; Haixue Kuang
Journal:  RSC Adv       Date:  2019-01-21       Impact factor: 4.036

Review 8.  Stem Cell Strategies to Evaluate Idiosyncratic Drug-induced Liver Injury.

Authors:  Winfried Krueger; Urs A Boelsterli; Theodore P Rasmussen
Journal:  J Clin Transl Hepatol       Date:  2014-09-15

9.  Real-time imaging of oxidative and nitrosative stress in the liver of live animals for drug-toxicity testing.

Authors:  Adam J Shuhendler; Kanyi Pu; Lina Cui; Jack P Uetrecht; Jianghong Rao
Journal:  Nat Biotechnol       Date:  2014-03-23       Impact factor: 54.908

Review 10.  Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation Plans.

Authors:  Franck A Atienzar; Eric A Blomme; Minjun Chen; Philip Hewitt; J Gerry Kenna; Gilles Labbe; Frederic Moulin; Francois Pognan; Adrian B Roth; Laura Suter-Dick; Okechukwu Ukairo; Richard J Weaver; Yvonne Will; Donna M Dambach
Journal:  Biomed Res Int       Date:  2016-09-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.